These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38502342)

  • 1. Attitudes, barriers, and facilitators to adherent completion of the recombinant zoster vaccine regimen in Canada: Qualitative interviews with healthcare providers and patients.
    George S; Regan J; Awan A; O'Connor M; Foster A; Raymond K; Gorfinkel I; McNeil SA
    Hum Vaccin Immunother; 2024 Dec; 20(1):2317595. PubMed ID: 38502342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations.
    Parikh R; Widenmaier R; Lecrenier N
    Expert Rev Vaccines; 2021 Sep; 20(9):1065-1075. PubMed ID: 34311643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence.
    Parikh R; Singer D; Chmielewski-Yee E; Dessart C
    Hum Vaccin Immunother; 2023 Dec; 19(3):2263979. PubMed ID: 37967254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review.
    Giannelos N; Ng C; Curran D
    Hum Vaccin Immunother; 2023 Dec; 19(1):2168952. PubMed ID: 36916240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
    McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
    Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant zoster vaccine (RZV) second-dose series completion in adults aged 50-64 years in the United States.
    Leung J; Gray EB; Anderson TC; Sharkey SM; Dooling K
    Vaccine; 2022 Nov; 40(50):7187-7190. PubMed ID: 36347721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An early look at the second dose completion of the recombinant zoster vaccine in Canadian adults: A retrospective database study.
    McGirr A; Bourgoin T; Wortzman M; Millson B; McNeil SA
    Vaccine; 2021 Jun; 39(25):3397-3403. PubMed ID: 34001346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations.
    Prosser LA; Harpaz R; Rose AM; Gebremariam A; Guo A; Ortega-Sanchez IR; Zhou F; Dooling K
    Ann Intern Med; 2019 Mar; 170(6):380-388. PubMed ID: 30776797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Public health impact of herpes zoster vaccination on older adults in Hong Kong.
    Chan PKS; Wong MCS; Chan M; Ching K; Giannelos N; Ng C
    Hum Vaccin Immunother; 2023 Dec; 19(1):2176065. PubMed ID: 36854447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials.
    López-Fauqued M; Co-van der Mee M; Bastidas A; Beukelaers P; Dagnew AF; Fernandez Garcia JJ; Schuind A; Tavares-da-Silva F
    Drug Saf; 2021 Jul; 44(7):811-823. PubMed ID: 34115324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary care physicians' experience with zoster vaccine live (ZVL) and awareness and attitudes regarding the new recombinant zoster vaccine (RZV).
    Hurley LP; Allison MA; Dooling KL; O'Leary ST; Crane LA; Brtnikova M; Beaty BL; Allen JA; Guo A; Lindley MC; Kempe A
    Vaccine; 2018 Nov; 36(48):7408-7414. PubMed ID: 30420121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?
    Han R; Gomez JA; de Veras B; Pinto T; Guzman-Holst A; Nieto J; van Oorschot DAM
    Hum Vaccin Immunother; 2023 Dec; 19(1):2164144. PubMed ID: 36821856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccines for preventing herpes zoster in older adults.
    Gagliardi AM; Andriolo BN; Torloni MR; Soares BG; de Oliveira Gomes J; Andriolo RB; Canteiro Cruz E
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31696946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors influencing series completion rates of recombinant herpes zoster vaccine in the United States: A retrospective pharmacy and medical claims analysis.
    Patterson BJ; Chen CC; McGuiness CB; Ma S; Glasser LI; Sun K; Buck PO
    J Am Pharm Assoc (2003); 2022; 62(2):526-536.e10. PubMed ID: 34893442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019.
    Patterson BJ; Chen CC; McGuiness CB; Glasser LI; Sun K; Buck PO
    Hum Vaccin Immunother; 2021 Aug; 17(8):2482-2487. PubMed ID: 33849373
    [No Abstract]   [Full Text] [Related]  

  • 16. Patterns of use of recombinant zoster vaccine among commercially-insured immunocompetent and immunocompromised adults 50-64 years old in the United States.
    Fix J; Vielot NA; Lund JL; Weber DJ; Smith JS; Hudgens MG; Becker-Dreps S
    Vaccine; 2023 Jan; 41(1):49-60. PubMed ID: 36396511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies.
    Mwakingwe-Omari A; Lecrenier N; Naficy A; Curran D; Posiuniene I
    Hum Vaccin Immunother; 2023 Dec; 19(3):2278362. PubMed ID: 37965770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50-59 years.
    Singer D; Salem A; Stempniewicz N; Ma S; Poston S; Curran D
    Vaccine; 2023 Aug; 41(37):5360-5367. PubMed ID: 37541822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insurance reimbursements for recombinant zoster vaccine in the private sector.
    Leidner AJ; Tang Z; Guo A; Anderson TC; Tsai Y
    Vaccine; 2021 Aug; 39(36):5091-5094. PubMed ID: 34348844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant zoster vaccine coverage in the United States: An analysis of claims-based data.
    Lewis CY; Mishra K; Sun Y; Sechrist SJ; Arnold BF; Acharya NR
    Vaccine; 2023 May; 41(23):3493-3496. PubMed ID: 37150621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.